相关实验视频

Updated: May 6, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

设计,合成和评估具有增强抗增殖活性的化莱因衍生物

Jiaojiao Li¹, Qili Zhang², Dan Wu³

¹College of Pharmacy, Gansu University of Chinese Medicine, 35 Dingxi East Road, Chengguan District, Lanzhou 730000, PR China.

Bioorganic chemistry

|October 31, 2025

概括

莱因的新型酸衍生物显示出增强的抗癌活性. 衍生物C9通过向CDK1并改善细胞透性,有效地抑制肝细胞癌 (HepG2) 细胞增殖.

科学领域:

药用化学医学化学
药理学药理学是指药理学的学科.
计算生物学计算生物学

背景情况:

莱因是一种天然的氨酸,具有抗癌性质,但其强度低,生物可用性差.
开发提高雷恩疗效的策略对于其治疗应用至关重要.

研究的目的:

为了合成新型酸衍生物的.
评估这些衍生物对癌症细胞系的抗增殖活性和作用机制.
调查这些衍生品作为改进的抗癌剂的潜力.

主要方法:

新型酸衍生物的合成.
针对各种癌症细胞系的抗增殖试验,包括人类肝细胞癌 (HepG2).
细胞机制研究 (迁移,细胞亡,细胞循环分析).
计算方法:分子动力学模拟和分子对接.
针对目标参与的ELISA验证.

主要成果:

衍生品C9对HepG2细胞表现出显著的抗增殖活性 (IC50 = 11.88 ± 0.93 μM),比rhein.
C9对正常肝细胞具有有利的选择性指数 (SI = 8.0).
机理学研究显示,C9抑制细胞迁移,诱导细胞亡,并在HepG2细胞中引起G2/M细胞周期停止.
计算模拟表明,C9的膜透性比C9更强.
CDK1被确定为直接的细胞内标,C9治疗降低了CDK1蛋白水平.

结论:

莱因的酸盐修饰增强了其抗增殖功效和生物可用性.
C9是一种有前途的化合物,具有改善的抗癌特性,向CDK1并表现出增强的细胞吸收.
进一步开发C9可能会导致肝细胞癌和其他癌症的新疗法策略.

关键词:

这是一种CDK1抑制剂.细胞循环逮捕细胞循环逮捕肝细胞癌是肝细胞癌.分子动力学模拟模型酸化是指酸化的方法.莱莱是一个

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...